Sign in

You're signed outSign in or to get full access.

Lauren Young

Director at Definitive Healthcare
Board

About Lauren Young

Lauren Young, age 42, has served on DH’s Board since July 2019. She is a Managing Director at Advent International and previously worked in the U.S. buyout fund at The Carlyle Group (2006–2009) and as an analyst at McColl Partners (2004–2006). She holds a B.A. from Davidson College and an MBA from Harvard Business School; the Board cites her financial knowledge and cross‑industry investment experience as core credentials . The Board has affirmatively determined she is independent under Nasdaq rules for Board service and specifically for the HCM & Compensation Committee, with the independence review explicitly considering her Advent role .

Past Roles

OrganizationRoleTenureCommittees/Impact
Advent International, L.P.Managing Director2011–presentPrivate equity leadership across business services, healthcare, industrial, consumer, and technology
The Carlyle Group (U.S. buyout fund)Investment professional (member of U.S. buyout fund)2006–2009Large‑cap PE execution experience
McColl PartnersAnalyst2004–2006Transaction analysis and deal support

External Roles

OrganizationRolePublic/PrivateNotes
CCC Intelligent Solutions Holdings Inc.DirectorPublicCurrent public company directorship
Iodine SoftwareDirectorPrivateCurrent private company directorship

Board Governance

  • Committee assignments: Member, HCM & Compensation Committee; Chair, Nominating & Corporate Governance Committee .
  • Independence: Board determined Ms. Young is independent for Board service and for HCM & Compensation Committee; independence determination considered her Advent employment .
  • Attendance: In 2024, the Board met 14 times; all directors attended at least 75% of Board and committee meetings during their period of service .
  • Board classification: Class I director; nominated for a three‑year term expiring at the 2028 annual meeting .
  • Nominating rights: Advent has contractual rights to designate two nominees while it holds ≥21.5% and one nominee while it holds ≥5%; Ms. Young is an Advent designee .
CommitteeMembershipChair2024 Meetings
Audit8
HCM & CompensationLauren YoungJill Larsen5
Nominating & Corporate GovernanceLauren YoungLauren Young4

Fixed Compensation

  • Policy: Standard non‑employee director cash retainer $50,000; Audit and HCM & Compensation Committee Chairs receive $20,000; Nominating & Governance Committee Chair receives $10,000; annual RSU grant valued at $175,000; initial RSU grant $300,000 upon joining .
  • Advent exemption: Directors employed by Advent or Spectrum Equity do not receive Board or committee compensation .
  • 2024 actuals for Lauren Young: No cash fees, no stock awards, no other compensation; no outstanding equity awards as of Dec 31, 2024 .
ComponentAmountNotes
Cash retainerAdvent employees do not receive director compensation
Committee chair feeNot applicable; compensated chairs must be eligible non‑employee directors
Equity (RSUs)No RSUs granted; no outstanding equity awards at year‑end

Performance Compensation

  • Stock‑based awards/Options: DH does not grant stock options with option‑like features; directors who are Advent employees receive no director equity; therefore Ms. Young has no performance‑linked director compensation .
  • Performance metrics: Company’s pay‑versus‑performance metrics (for executives) include Adjusted EBITDA Margin, Annual Recurring Revenue, Stock Price, Relative TSR, Net Dollar Retention, and % ARR from enterprise customers; these do not apply to Ms. Young’s director pay (none) .

Other Directorships & Interlocks

  • Advent interlocks: Ms. Young is an Advent Managing Director; Advent is DH’s largest holder (57.0% of Class A as of April 1, 2025) and has nominating rights; Board considered Advent roles in independence determinations .
  • Voting agreement: Advent agreed to vote any shares exceeding 40.3% of outstanding voting securities proportionally with non‑Advent stockholders, mitigating control concerns after the November 2024 repurchase program .
  • Related party transaction: DH entered into a master services agreement with Encora in Nov 2024 (~$1.7 million commitment over one year); Advent owns a majority voting interest in Encora’s parent—potential related‑party exposure .

Expertise & Qualifications

  • Education: B.A. (Davidson College); MBA (Harvard Business School) .
  • Domain expertise: Financial analysis, private equity investing across software and technology; service as director at software solutions companies .
  • Board qualification: The Board cites financial knowledge, investment experience across industries, and relevant director service as reasons for nomination .

Equity Ownership

  • Individual beneficial ownership: Lauren Young shows no reported Class A or Class B shares as of April 1, 2025, with a footnote disclaiming Advent fund holdings except for any pecuniary interest .
  • Outstanding shares baseline: 109,544,357 Class A and 38,996,613 Class B shares outstanding as of April 1, 2025 .
  • Director ownership guidelines: Apply to non‑employee directors, but exclude directors who do not receive Board compensation because their principal employment is with an investment fund that invests in DH (Advent employees); directors must reach ≥3x annual cash retainer within 5 years if subject to guidelines; as of Dec 31, 2024, all subject directors met tenure‑appropriate levels .
HolderClass A Shares% Class AClass B Shares% Class BNotes
Lauren YoungDisclaims Advent fund holdings except for pecuniary interest
Advent funds (aggregate)62,493,67657.0%Largest holder; subject to voting agreement on “excess voting securities”

Governance Assessment

  • Strengths: Independent determination despite sponsor affiliation; chairs Nominating & Governance and serves on HCM & Compensation; strong attendance culture (≥75% across Board/committees); proportional voting agreement for Advent mitigates outsized control risk .
  • Alignment: Ms. Young receives no director cash or equity due to Advent employment; individual “skin‑in‑the‑game” alignment relies on any indirect pecuniary interest through Advent rather than personal DH shareholdings; she is exempt from director ownership guidelines .
  • Conflicts/Related‑party exposure: Advent nominating rights and majority ownership create potential influence; Encora agreement (~$1.7m) with an Advent‑controlled affiliate is a related‑party transaction requiring ongoing Audit Committee oversight .
  • RED FLAGS: Sponsor‑affiliated director serving as Nominating & Governance Chair may raise independence optics; absence of personal DH share ownership and no director equity could weaken direct alignment; recurring sponsor transactions (e.g., Encora) heighten conflict monitoring needs .